Fimepinostat (CUDC-907) has been used in trials studying the treatment of lymphoma, solid tumors, breast cancer, multiple myeloma, and NUT midline carcinoma, among others.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.